Using a dichotomous scoring criteria, Baltaci et al. reported Bcl-2 expression in 12 of 15 HGPIN lesions and 12 of 18 LGPIN lesions, with staining present in both basal and luminal layers, as opposed to basal staining only in BPH samples.[35] Johnson et al. found Bcl-2 overexpression in 34.9% cases of HGPIN.[13] In our study, there were essentially no differences in Bcl-2 across the pre-cancer tissue compartments.[13,36,37] The basal cell compartment and the positive control sample (tonsil) displayed consistently strong expression of Bcl-2, indicating that assay conditions were optimized. Here, BCL2 is linked to benign prostatic hyperplasia.